Replies to post #124025 on Biotech Values

[sodrock]

I for one am happy we have a glimpse into this trial and also found it odd that the sell side analysts ignored the remainder after the second day. Sounds very promising.

[DFRAI]

"It was TEVA that chose to separate the inequitable trial and have it first" they - teva, allways want to take the easy path - knowing that it is the hardest to prove...and to claim victory...cheap shots taken.

[RockRat]

>>"those who didn't enter the courtroom or did not want to come in after the first 48 hours probably missed the most important aspect of the inequitable conduct trial. That was during the closing arguments when the depositions were entered from other people that were in the room with Dr. Pinchasi who stated completely the opposite of what she testified to."<<

You get snips of this in at least one of the documents made available by Patrick, relating to Pinchasi's conduct in the initial submission of the '037 patent. See page 225 - 230 of DEFENDANTS SANDOZ INC. AND MOMENTA PHARMACEUTICALS, INC.’S OPPOSITION TO PLAINTIFFS’ PROPOSED FINDINGS OF FACT AND CONCLUSIONS OF LAW:

https://docs.google.com/open?id=0BwViTbG4AHwYYTYyNWRlNDYtNzRhYi00OWEzLWI4MzMtOGY1MzIzYmM2YzAy

It recalls to me the same sort of cherry picking and withholding of data that torpedoed Sanofi's patents relating to enoxaparin.

She seems to contradict herself and other documentary evidence, too. She is a key witness, and I don't find her very credible.

Regards, RockRat